Repligen Corporation $RGEN Shares Acquired by First Trust Advisors LP

First Trust Advisors LP increased its position in shares of Repligen Corporation (NASDAQ:RGEN) by 3.8% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 261,583 shares of the biotechnology company’s stock after purchasing an additional 9,473 shares during the period. First Trust Advisors LP’s holdings in Repligen were worth $32,536,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD raised its holdings in shares of Repligen by 6.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company’s stock worth $962,711,000 after purchasing an additional 430,039 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in Repligen by 3,219.3% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 413,425 shares of the biotechnology company’s stock worth $51,422,000 after acquiring an additional 400,970 shares during the last quarter. Geneva Capital Management LLC boosted its stake in Repligen by 239.6% in the second quarter. Geneva Capital Management LLC now owns 487,534 shares of the biotechnology company’s stock valued at $60,639,000 after acquiring an additional 343,991 shares during the period. Blue Whale Capital LLP bought a new position in shares of Repligen during the second quarter valued at approximately $35,782,000. Finally, Nuveen LLC bought a new position in shares of Repligen during the first quarter valued at approximately $35,536,000. Institutional investors own 97.64% of the company’s stock.

Repligen Stock Performance

RGEN stock opened at $163.80 on Thursday. The company has a market capitalization of $9.22 billion, a P/E ratio of 8,194.10, a PEG ratio of 3.61 and a beta of 1.11. The company has a 50-day simple moving average of $155.50 and a 200 day simple moving average of $134.03. Repligen Corporation has a fifty-two week low of $102.96 and a fifty-two week high of $182.52. The company has a quick ratio of 7.14, a current ratio of 8.36 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 EPS for the quarter, beating the consensus estimate of $0.42 by $0.04. Repligen had a net margin of 0.25% and a return on equity of 4.66%. The firm had revenue of $188.81 million for the quarter, compared to analysts’ expectations of $181.23 million. During the same quarter last year, the company earned $0.43 EPS. Repligen’s quarterly revenue was up 21.9% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. Sell-side analysts predict that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Insider Activity at Repligen

In related news, COO James Bylund sold 2,191 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total transaction of $331,301.11. Following the sale, the chief operating officer owned 21,520 shares of the company’s stock, valued at $3,254,039.20. The trade was a 9.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Anthony Hunt sold 20,000 shares of the stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $154.61, for a total value of $3,092,200.00. Following the transaction, the director directly owned 80,743 shares of the company’s stock, valued at approximately $12,483,675.23. The trade was a 19.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 49,382 shares of company stock worth $7,676,802. 1.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Evercore ISI boosted their price objective on Repligen from $155.00 to $175.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Hsbc Global Res upgraded Repligen to a “strong-buy” rating in a research note on Wednesday, October 1st. Barclays upped their price target on shares of Repligen from $160.00 to $175.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. Wall Street Zen cut shares of Repligen from a “buy” rating to a “hold” rating in a report on Tuesday, November 4th. Finally, Jefferies Financial Group set a $160.00 target price on shares of Repligen and gave the company a “hold” rating in a research note on Tuesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $173.85.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.